United Therapeutics Stock (NASDAQ:UTHR)
Previous Close
$360.71
52W Range
$208.62 - $417.82
50D Avg
$363.50
200D Avg
$300.17
Market Cap
$16.27B
Avg Vol (3M)
$370.68K
Beta
0.56
Div Yield
-
UTHR Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
UTHR Performance
Peer Comparison
Ticker | Company |
---|---|
NUVL | Nuvalent, Inc. |
INCY | Incyte Corporation |
AKRO | Akero Therapeutics, Inc. |
KNSA | Kiniksa Pharmaceuticals, Ltd. |
APLS | Apellis Pharmaceuticals, Inc. |
LRMR | Larimar Therapeutics, Inc. |
BPMC | Blueprint Medicines Corporation |
DAWN | Day One Biopharmaceuticals, Inc. |
VTYX | Ventyx Biosciences, Inc. |
BGNE | BeiGene, Ltd. |
ALNY | Alnylam Pharmaceuticals, Inc. |
REPL | Replimune Group, Inc. |
LEGN | Legend Biotech Corporation |
ASND | Ascendis Pharma A/S |
MNKD | MannKind Corporation |
PCVX | Vaxcyte, Inc. |
RARE | Ultragenyx Pharmaceutical Inc. |